Print Page | Sign In | Join Today
News & Press: Company News

CEL-SCI Brings in $13M with Offering and Warrants

Tuesday, April 29, 2014  
Share |
CEL-SCI Corporation a late-stage oncology company, announced today that it has received approximately $3 million through the exercise of warrants by investors to purchase the Company's common stock over the past 45 days. These $3 million are in addition to the $10 million raised in a public offering that closed on April 17, 2014. Proceeds from the warrant exercises and the public offering will be used to fund CEL-SCI's Phase III head and neck cancer clinical trial, other research and development, and general and administrative expenses.

"The additional funding is helping us execute the clinical development programs for our investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection), both for the global Phase III trial for head and neck cancer and, with the U.S. Navy as a development partner, under a Cooperative Agreement for anal warts in HIV/HPV co-infected men and women", said Geert Kersten, Chief Executive Officer of CEL-SCI.

"With this financing we welcome a diverse group of about 250 high net worth retail investors to our shareholder base,"  Kersten said regarding the public offering.

Our Sponsors

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected